Kathleen Meyer

669 total citations
23 papers, 469 citations indexed

About

Kathleen Meyer is a scholar working on Molecular Biology, Genetics and Physiology. According to data from OpenAlex, Kathleen Meyer has authored 23 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 11 papers in Genetics and 7 papers in Physiology. Recurrent topics in Kathleen Meyer's work include Virus-based gene therapy research (11 papers), CRISPR and Genetic Engineering (11 papers) and Lysosomal Storage Disorders Research (6 papers). Kathleen Meyer is often cited by papers focused on Virus-based gene therapy research (11 papers), CRISPR and Genetic Engineering (11 papers) and Lysosomal Storage Disorders Research (6 papers). Kathleen Meyer collaborates with scholars based in United States and Canada. Kathleen Meyer's co-authors include Michael C. Holmes, Thomas Wechsler, Susan S. Martin, Scott Sproul, Michelle Rohde, Chester B. Whitley, R. Scott McIvor, Robert Radeke, Kelly M. Podetz-Pedersen and Russell C. DeKelver and has published in prestigious journals such as Blood, Cancer Research and The Journal of Pediatrics.

In The Last Decade

Kathleen Meyer

22 papers receiving 455 citations

Peers

Kathleen Meyer
Enyu Ding United States
Maribeth Cherry United States
Fédor Svinartchouk France
Katie Campbell United States
Manal Morsy United States
Sherry Koontz United States
Scott Sproul United States
Beth McCullough United States
Valérie Risson France
Elisa Masat Italy
Enyu Ding United States
Kathleen Meyer
Citations per year, relative to Kathleen Meyer Kathleen Meyer (= 1×) peers Enyu Ding

Countries citing papers authored by Kathleen Meyer

Since Specialization
Citations

This map shows the geographic impact of Kathleen Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Meyer more than expected).

Fields of papers citing papers by Kathleen Meyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Meyer. The network helps show where Kathleen Meyer may publish in the future.

Co-authorship network of co-authors of Kathleen Meyer

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen Meyer. A scholar is included among the top collaborators of Kathleen Meyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen Meyer. Kathleen Meyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nguyen, Hoang-Oanh B., Sumita Bhardwaj, David A. Shivak, et al.. (2024). A robust and flexible baculovirus-insect cell system for AAV vector production with improved yield, capsid ratios and potency. Molecular Therapy — Methods & Clinical Development. 32(2). 101228–101228. 8 indexed citations
2.
Meyer, Kathleen, et al.. (2024). A 3-month gene therapy single-dose IV administration pharmacology and safety study with ST-920 (isaralgagene civaparvovec) for Fabry disease in mice. Molecular Genetics and Metabolism. 141(2). 107963–107963. 1 indexed citations
3.
Pan, Yonghua, et al.. (2023). A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies. Molecular Therapy — Methods & Clinical Development. 31. 101126–101126. 8 indexed citations
4.
Moffit, Jeffrey S., Diann Blanset, Jessica Lynch, et al.. (2022). Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies. Human Gene Therapy. 33(21-22). 1126–1141. 11 indexed citations
5.
Harmatz, Paul, Carlos E. Prada, Barbara K. Burton, et al.. (2022). First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia B. Molecular Therapy. 30(12). 3587–3600. 50 indexed citations
6.
Ledeboer, Annemarie, et al.. (2022). Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials. Gene Therapy. 30(1-2). 150–159. 18 indexed citations
7.
Pagant, Silvère, Luciana Moreira, Lin Gan, et al.. (2021). ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice. Molecular Therapy. 29(11). 3230–3242. 13 indexed citations
8.
Yasuda, Makiko, Silvère Pagant, Lin Gan, et al.. (2020). AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Molecular Therapy — Methods & Clinical Development. 18. 607–619. 41 indexed citations
9.
Lombaert, Isabelle M.A., Vaishali Patel, Matthew R. Moore, et al.. (2020). CERE-120 Prevents Irradiation-Induced Hypofunction and Restores Immune Homeostasis in Porcine Salivary Glands. Molecular Therapy — Methods & Clinical Development. 18. 839–855. 32 indexed citations
10.
11.
Ou, Li, Russell C. DeKelver, Michelle Rohde, et al.. (2018). ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome. Molecular Therapy. 27(1). 178–187. 64 indexed citations
12.
Laoharawee, Kanut, Russell C. DeKelver, Kelly M. Podetz-Pedersen, et al.. (2018). Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing. Molecular Therapy. 26(4). 1127–1136. 91 indexed citations
13.
Ando, Dale & Kathleen Meyer. (2017). Gene Editing. Hematology/Oncology Clinics of North America. 31(5). 797–808. 7 indexed citations
14.
DiGiusto, David, Paula M. Cannon, Michael C. Holmes, et al.. (2016). Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Molecular Therapy — Methods & Clinical Development. 3. 16067–16067. 85 indexed citations
15.
Riley, Brigit E., Dominique Cartier, Kate Nesbitt, et al.. (2016). Development of an Optimized rAAV2/6 Human Factor 8 cDNA Vector Cassette for Hemophilia a Gene Therapy. Blood. 128(22). 1173–1173. 1 indexed citations
16.
Wechsler, Thomas, Kathleen Meyer, S. Kaye Spratt, et al.. (2015). ZFN-Mediated Gene Targeting at the Albumin Locus in Liver Results in Therapeutic Levels of Human FIX in Mice and Non-Human Primates. Blood. 126(23). 200–200. 3 indexed citations
17.
Pryer, Nancy, Victoria Sung, Ursula Jeffry, et al.. (2009). Abstract #DDT02-2: MCS110: a monoclonal antibody with potent neutralizing activity against macrophage colony-stimulating factor for the treatment of tumor-induced osteolysis. Cancer Research. 69. 1 indexed citations
18.
19.
20.
Meyer, Kathleen, et al.. (1985). Adenovirus associated with congenital pleural effusion. The Journal of Pediatrics. 107(3). 433–435. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Enyu Ding Breakdown of academic impact, for papers by Maribeth Cherry Breakdown of academic impact, for papers by Fédor Svinartchouk Breakdown of academic impact, for papers by Katie Campbell Breakdown of academic impact, for papers by Manal Morsy Breakdown of academic impact, for papers by Sherry Koontz Breakdown of academic impact, for papers by Scott Sproul Breakdown of academic impact, for papers by Beth McCullough Breakdown of academic impact, for papers by Valérie Risson Breakdown of academic impact, for papers by Elisa Masat
Rankless by CCL
2026